Pulmonary arterial hypertension (PAH) is a devastating disease characterized by arteriopathy in the small to medium-sized distal pulmonary arteries, often accompanied by infiltration of inflammatory ...

Pulmonary arterial hypertension is a rare form of pulmonary hypertension that poses diagnostic challenges and often comes with a delayed diagnosis. Pulmonary hypertension (PH) is organized into 5 ...

Pulmonary arterial hypertension is a progressive disease involving proliferative remodeling of the pulmonary vessels. Despite therapeutic advances, the disease-associated morbidity and mortality ...

Though circulating high mobility group box-1 levels appear to be a biomarker for pulmonary arterial hypertension (PAH) in adults with congenital heart disease, the same is not true in pediatric ...

Sotatercept, an activin-signaling inhibitor, reduces morbidity and mortality among patients with long-standing pulmonary arterial hypertension. Its effects in patients with pulmonary arterial ...

Pulmonary arterial hypertension (PAH) is a rare and severe lung disease with a life-threatening prognosis. After several positive trials, a recent study has confirmed the efficacy of a biotherapy, ...

Winrevair, also known as sotatercept-csrk, is a medicine used to treat pulmonary arterial hypertension (PAH), which causes high blood pressure in the arteries that go from your heart to your lungs.

Expert Rev Cardiovasc Ther. 2012;10(11):1367-1373. The elderly merit special consideration for BP measurement. These hypertensive patients are prone to have autonomic failure with postural hypotension ...

Hypertension is one of the most prevalent non-transmittable diseases in the world, with 29% of the world's population expected to suffer from the condition by 2025. Despite substantial advances in ...